Savara (SVRA) Debt Ratio (2015 - 2026)
Savara (SVRA) reported Debt Ratio of 0.14 for Q1 2026, down 13.02% year-over-year from 0.16 in Q1 2025, and up 14.95% on a QoQ basis from 0.12 in Q4 2025.
Savara (SVRA) has 12 years of Debt Ratio data on file, last reported at 0.14 in Q1 2026.
- Quarterly Debt Ratio fell 13.02% year-over-year to 0.14 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.14 (down 13.02% YoY) and the FY2025 annual result came in at 0.12, down 5.63% from the prior year.
- Debt Ratio rose to 0.14 in Q1 2026 per SVRA's latest filing, from 0.12 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.22 in Q2 2023 and bottomed at 0.11 in Q3 2024.
- The 5-year median for Debt Ratio is 0.17 (2022), against an average of 0.16.
- The widest annual swing landed in 2024, when Debt Ratio retreated 22.97%; it then jumped 90.07% in 2025.
- Tracing SVRA's Debt Ratio over 5 years: stood at 0.19 in 2022, then slipped by 20.47% to 0.15 in 2023, then dropped by 15.73% to 0.13 in 2024, then fell by 5.63% to 0.12 in 2025, then grew by 14.95% to 0.14 in 2026.
- Per Business Quant, the three latest SVRA Debt Ratio figures stand at 0.14 (Q1 2026), 0.12 (Q4 2025), and 0.21 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 0.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.14 |
| Dec 31, 2025 | 0.12 |
| Sep 30, 2025 | 0.21 |
| Jun 30, 2025 | 0.18 |
| Mar 31, 2025 | 0.16 |
| Dec 31, 2024 | 0.13 |
| Sep 30, 2024 | 0.11 |
| Jun 30, 2024 | 0.19 |
| Mar 31, 2024 | 0.17 |
| Dec 31, 2023 | 0.15 |
| Sep 30, 2023 | 0.14 |
| Jun 30, 2023 | 0.22 |
| Mar 31, 2023 | 0.20 |
| Dec 31, 2022 | 0.19 |
| Sep 30, 2022 | 0.18 |
| Jun 30, 2022 | 0.17 |
| Mar 31, 2022 | 0.16 |
| Dec 31, 2021 | 0.15 |
| Sep 30, 2021 | 0.14 |
| Jun 30, 2021 | 0.13 |
| Mar 31, 2021 | 0.12 |
| Dec 31, 2020 | 0.26 |
| Sep 30, 2020 | 0.23 |
| Jun 30, 2020 | 0.22 |
| Mar 31, 2020 | 0.21 |
| Dec 31, 2019 | 0.18 |
| Sep 30, 2019 | 0.18 |
| Jun 30, 2019 | 0.17 |
| Mar 31, 2019 | 0.17 |
| Dec 31, 2018 | 0.16 |
| Sep 30, 2018 | 0.10 |
| Jun 30, 2018 | 0.13 |
| Mar 31, 2018 | 0.12 |
| Dec 31, 2017 | 0.09 |
| Sep 30, 2017 | 0.12 |
| Jun 30, 2017 | 0.12 |
| Mar 31, 2017 | 0.25 |
| Dec 31, 2016 | 0.13 |
| Sep 30, 2016 | 0.35 |
| Jun 30, 2016 | 0.31 |
| Mar 31, 2016 | 0.30 |
| Dec 31, 2015 | 0.27 |
| Sep 30, 2015 | 0.23 |
| Jun 30, 2015 | 0.00 |
| Mar 31, 2015 | 0.00 |